Which has higher valuation & earnings, IMMX or TYRA?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A

Is IMMX or TYRA more profitable?

Tyra Biosciences' return on equity of -42.66% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Tyra Biosciences N/A -42.66% -39.79%

Does the media refer more to IMMX or TYRA?

In the previous week, Tyra Biosciences had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Tyra Biosciences and 3 mentions for Immix Biopharma. Tyra Biosciences' average media sentiment score of 1.66 beat Immix Biopharma's score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor STOK or IMMX?

In the previous week, Stoke Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Stoke Therapeutics and 3 mentions for Immix Biopharma. Stoke Therapeutics' average media sentiment score of 1.23 beat Immix Biopharma's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, IMMX or DMRA?

Immix Biopharma is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is IMMX or DMRA more profitable?

Immix Biopharma's return on equity of -73.24% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Does the media refer more to IMMX or DMRA?

In the previous week, Damora Therapeutics, Inc. Common Stock had 13 more articles in the media than Immix Biopharma. MarketBeat recorded 16 mentions for Damora Therapeutics, Inc. Common Stock and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.00 beat Damora Therapeutics, Inc. Common Stock's score of -0.17 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor IMMX or MRVI?

In the previous week, Maravai LifeSciences had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Maravai LifeSciences and 3 mentions for Immix Biopharma. Maravai LifeSciences' average media sentiment score of 0.15 beat Immix Biopharma's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, IMMX or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is IMMX or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Bicara Therapeutics N/A -35.89% -33.78%

Does the media favor IMMX or BCAX?

In the previous week, Bicara Therapeutics had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Immix Biopharma. Bicara Therapeutics' average media sentiment score of 1.22 beat Immix Biopharma's score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immix Biopharma (IMMX) Competitors

$8.32 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$8.32 +0.00 (+0.06%)

As of 07/31/2026 07:34 PM Eastern

Compare

IMMX vs. TYRA, STOK, DMRA, MRVI, and BCAX

Should you buy Immix Biopharma stock or one of its competitors? MarketBeat compares Immix Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immix Biopharma include Tyra Biosciences (TYRA), Stoke Therapeutics (STOK), Damora Therapeutics, Inc. Common Stock (DMRA), Maravai LifeSciences (MRVI), and Bicara Therapeutics (BCAX).

How does Immix Biopharma compare to Tyra Biosciences?

Immix Biopharma (NASDAQ:IMMX) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tyra Biosciences is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Immix Biopharma currently has a consensus target price of $20.71, indicating a potential upside of 148.97%. Tyra Biosciences has a consensus target price of $47.00, indicating a potential upside of 47.43%. Given Immix Biopharma's higher possible upside, research analysts plainly believe Immix Biopharma is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Tyra Biosciences' return on equity of -42.66% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Tyra Biosciences	N/A	-42.66%	-39.79%

Immix Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

In the previous week, Tyra Biosciences had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Tyra Biosciences and 3 mentions for Immix Biopharma. Tyra Biosciences' average media sentiment score of 1.66 beat Immix Biopharma's score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Tyra Biosciences beats Immix Biopharma on 9 of the 14 factors compared between the two stocks.

How does Immix Biopharma compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Stoke Therapeutics currently has a consensus price target of $43.00, indicating a potential upside of 49.00%. Immix Biopharma has a consensus price target of $20.71, indicating a potential upside of 148.97%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

11.3% of Immix Biopharma shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than Immix Biopharma. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$32.08M	56.03	-$6.89M	-$2.81	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

In the previous week, Stoke Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Stoke Therapeutics and 3 mentions for Immix Biopharma. Stoke Therapeutics' average media sentiment score of 1.23 beat Immix Biopharma's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immix Biopharma has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Immix Biopharma	N/A	-73.24%	-59.20%

Summary

Stoke Therapeutics beats Immix Biopharma on 9 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Immix Biopharma (NASDAQ:IMMX) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Damora Therapeutics, Inc. Common Stock had 13 more articles in the media than Immix Biopharma. MarketBeat recorded 16 mentions for Damora Therapeutics, Inc. Common Stock and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.00 beat Damora Therapeutics, Inc. Common Stock's score of -0.17 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Immix Biopharma's return on equity of -73.24% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Immix Biopharma is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Immix Biopharma has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Immix Biopharma currently has a consensus target price of $20.71, suggesting a potential upside of 148.97%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $44.00, suggesting a potential upside of 51.78%. Given Immix Biopharma's higher probable upside, equities research analysts clearly believe Immix Biopharma is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

Immix Biopharma beats Damora Therapeutics, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Immix Biopharma compare to Maravai LifeSciences?

Immix Biopharma (NASDAQ:IMMX) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Maravai LifeSciences and 3 mentions for Immix Biopharma. Maravai LifeSciences' average media sentiment score of 0.15 beat Immix Biopharma's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immix Biopharma currently has a consensus price target of $20.71, indicating a potential upside of 148.97%. Maravai LifeSciences has a consensus price target of $5.50, indicating a potential downside of 16.29%. Given Immix Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immix Biopharma is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Immix Biopharma has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immix Biopharma has a beta of 0.11, suggesting that its share price is 89% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Immix Biopharma has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Maravai LifeSciences	$204.73M	8.29	-$130.77M	-$0.71	N/A

Summary

Maravai LifeSciences beats Immix Biopharma on 8 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Bicara Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

11.3% of Immix Biopharma shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Immix Biopharma presently has a consensus target price of $20.71, suggesting a potential upside of 148.97%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 11.71%. Given Immix Biopharma's higher probable upside, equities research analysts plainly believe Immix Biopharma is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Immix Biopharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.81, suggesting that its stock price is 181% less volatile than the broader market.

In the previous week, Bicara Therapeutics had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Immix Biopharma. Bicara Therapeutics' average media sentiment score of 1.22 beat Immix Biopharma's score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics' return on equity of -35.89% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Summary

Immix Biopharma and Bicara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMX vs. The Competition

Export

Metric	Immix Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$452.69M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-9.04	7.38	282.30	24.66
Price / Sales	N/A	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	4.70	16.96	10.96	6.07
Net Income	-$29.44M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-4.26%	-1.77%	-0.64%	-0.44%
1 Month Performance	-19.54%	-8.39%	-5.23%	-4.81%
1 Year Performance	213.96%	48.40%	61.97%	18.61%

Immix Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMX Immix Biopharma	2.3399 of 5 stars	$8.32 flat	$20.71 +149.0%	+214.0%	$452.69M	N/A	N/A	9
TYRA Tyra Biosciences	3.1442 of 5 stars	$31.11 +0.7%	$47.00 +51.1%	+207.4%	$1.84B	N/A	N/A	20	News Coverage Positive News Gap Up
STOK Stoke Therapeutics	2.7463 of 5 stars	$29.48 +0.3%	$43.00 +45.9%	+123.5%	$1.83B	$184.42M	N/A	100	Positive News Gap Up
DMRA Damora Therapeutics, Inc. Common Stock	2.0706 of 5 stars	$28.33 -3.7%	$43.38 +53.1%	+798.9%	$1.81B	N/A	N/A	40	Upcoming Earnings
MRVI Maravai LifeSciences	1.5308 of 5 stars	$6.59 -3.9%	$5.50 -16.5%	+195.9%	$1.77B	$185.74M	N/A	610	Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immix Biopharma (IMMX) Competitors

IMMX vs. TYRA, STOK, DMRA, MRVI, and BCAX

How does Immix Biopharma compare to Tyra Biosciences?

Summary

How does Immix Biopharma compare to Stoke Therapeutics?

Summary

How does Immix Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Immix Biopharma compare to Maravai LifeSciences?

Summary

How does Immix Biopharma compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immix Biopharma (IMMX) Competitors

IMMX vs. TYRA, STOK, DMRA, MRVI, and BCAX

How does Immix Biopharma compare to Tyra Biosciences?

Do institutionals and insiders believe in IMMX or TYRA?

Which has higher valuation & earnings, IMMX or TYRA?

Do analysts rate IMMX or TYRA?

Is IMMX or TYRA more profitable?

Which has more risk and volatility, IMMX or TYRA?

Does the media refer more to IMMX or TYRA?

Summary

How does Immix Biopharma compare to Stoke Therapeutics?

Do analysts rate STOK or IMMX?

Do institutionals & insiders hold more shares of STOK or IMMX?

Which has more risk & volatility, STOK or IMMX?

Which has higher earnings and valuation, STOK or IMMX?

Does the media favor STOK or IMMX?

Is STOK or IMMX more profitable?

Summary

How does Immix Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Do institutionals and insiders have more ownership in IMMX or DMRA?

Does the media refer more to IMMX or DMRA?

Is IMMX or DMRA more profitable?

Which has stronger valuation & earnings, IMMX or DMRA?

Which has more volatility and risk, IMMX or DMRA?

Do analysts rate IMMX or DMRA?

Summary

How does Immix Biopharma compare to Maravai LifeSciences?

Does the media favor IMMX or MRVI?

Do analysts prefer IMMX or MRVI?

Is IMMX or MRVI more profitable?

Do institutionals & insiders have more ownership in IMMX or MRVI?

Which has more risk and volatility, IMMX or MRVI?

Which has better valuation and earnings, IMMX or MRVI?

Summary

How does Immix Biopharma compare to Bicara Therapeutics?

Do institutionals and insiders have more ownership in IMMX or BCAX?

Which has higher valuation & earnings, IMMX or BCAX?

Do analysts prefer IMMX or BCAX?

Which has more risk & volatility, IMMX or BCAX?

Does the media favor IMMX or BCAX?

Is IMMX or BCAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools